News
02/22/2023
SRI scientists are developing therapeutics to help fight the next pandemic
SRI International, an independent nonprofit research institute, has been awarded a $4.95 million contract, with options to fund up to $21 million, from the National Institute of Allergy and Infectious Diseases (NIAID) to develop drugs to increase the nation’s therapeutic arsenal against new or existing viral pathogens. The funds are part of the US government’s …
02/14/2023
Virginia Invests $66.7 Million to Expand Commonwealth’s Life Sciences Industry
Governor Glenn Youngkin announced more than $66 million in state grants for four projects within the Biotechnology, Life Sciences and Pharmaceutical Manufacturing Cluster. These projects provide job creation, wage expansion, and broader economic growth throughout the Commonwealth. “In order to make Virginia a leader in biotechnology, life sciences and pharmaceutical manufacturing, we have to accelerate …
02/09/2023
CytoRecovery Awarded National Science Foundation Phase II SBIR Research Grant
CytoRecovery, Inc., a leader in marker free technologies for the enrichment, sorting, and recovery of live cells, announced that the National Science Foundation (NSF) has approved its application to receive a Phase II SBIR Research Grant. Titled “Bioelectrical Cell Enrichment, Sorting, and Recovery with On-Chip Sample Prep and Monitoring,” the grant will provide $952,558 in …
02/01/2023
Engineered BioPharmaceuticals to Expand in Virginia
Governor Glenn Youngkin announced that Engineered BioPharmaceuticals, Inc., a pharmaceutical engineering and manufacturing company dedicated to advancing cost effective, state-of-the-art medicine, will invest $6.1 million to expand in the City of Danville. The company will expand from its current lab space in the Dan River Business Development Center into its first standalone manufacturing facility at …
02/01/2023
Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced it has entered into an option agreement for the sale of the assets of Purnovate, Inc. (“Purnovate”), a wholly owned subsidiary of Adial, to Adenomed, LLC (“Adenomed”), a new company formed by Purnovate …
01/31/2023
AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia
AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic pain syndromes, such as fibromyalgia. Revealed in the peer-reviewed journal Lupus Science and Medicine, the paper details AMPEL’s breakthrough approach to characterize the underlying disease activity from gene expression data obtained from patient blood samples. The FibroGENE® lab …